Dr. T. Raja is a renowned Oncologist in Greams Road, Chennai. He has been a practicing Oncologist for 33 years. He has presented 5 International conferences and 5 National Conferences Recognition and Management of childhood acute Lymphoblastic Leukemia Peripheral Hospitals Indian Journal of Practical Pediatrics, Vol. 5 No 4 Oct-Dec 1997: 323 Amifostine, For Drug Review Ind. J MED & PED Oncol 1995, Vol.16:68-69 Chemotheraphy of Gastrointestinal Malignancies Ind J MED & PED Oncol 1995, Vol. 16: 93-98 Priapism in a child with Pelvic Rhabdomyosarcoma, A case report and review of Literature Ind J MED & PED Oncol 1995, Vol 16: 188-191.

Dr. T. Raja is Director od Medical Oncology at Apollo Speciality Cancer Hospital. He completed MBBS from Madurai Kamaraj University, MD-Pediatrics from Gujarat University and DM-Oncology from Gujarat University. He is a member of Indian Medical Association (IMA). Some of the services provided by the doctor are PICC Line Insertion, Stem Cell Transplantation, Human Papilloma Virus - HPV, Melanoma Treatment and Lung Cancer Treatment.

Educational Qualifications:

• MBBS - Madurai Kamaraj University, 1988
• MD - Pediatrics - Gujarat University, India, 1993
• DM - Oncology - Gujarat University, India, 1997

Professional Memberships:

• ESMO Asia CME Partner Centers – Colorectal Cancer Program
• Indian society of medical and pediatric oncology(ISMPO)
• Indian society of oncology (ISO)
• Association of physicians of India(IAP)
• European society of Bone marrow transplants(EBMT)
• Elected as a member 2009, for the executive committee ISO
• Member ICON : Indian Cooperative Oncology Network

Presently Dr. T Raja is associated as Director Medical Oncology at Apollo Hospital, Greams Road, Chennai.

• DNB Medical Oncology Teacher. (Sub Speciality Teaching Program) in Apollo Speciality Hospital, Tamil Nadu, Chennai,India- from 2014.
• Senior Consultant in MedicalOncology& Senior Consultant in BMT in Apollo Speciality Hospital, Tamil Nadu, Chennai,India- From 1999 to till date
• Member of the Inspection Commission in University of Madras, Tamil Nadu, Chennai, India- 2011
• DNB Medical Oncology Teacher in V.S. Hospital, Tamil Nadu, Chennai, India- 2009
• Adjunt Associate ProfessorUniversity of Queensland, School of Medicine, Brisbane- 2009
• Junior Consultant in MedicalOncology and BMT Apollo Speciality Hospital,Tamil Nadu, Chennai, India- From 1997 Sep to 1999 Jan
• Senior Registrar in Apollo Speciality Hospital, Tamil Nadu, Chennai, India- From 1996 to 1997 Sep
• Honorary Observer in BMT The Royal Free Hospitals, London- From 1998 to 1998 Jul
• April 2015 to till date Breast Cancer Registry to Collate Data on Epidemiology andTreatment Patterns & Outcomes of Breast Cancer in India
• 2012 A randomized, controlled, double-blind Phase III trial to compare the efficacy, safety and pharmacokinetics of GP2013 plus cyclophosphamide, vincristine, prednisone vs.MabThera® plus cyclophosphamide, vincristine,prednisone, followed by GP2013 or MabThera® maintenance therapy in patients with previously untreated, advanced stage follicular lymphoma.
• From 2012 to till dateA randomized, two-arm, open-label, multicenter Phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first line patients with HER2-positive and hormone receptor-positive advanced (metastatic or locally advanced) breast cancer
• From 2012 to till dateA Randomised, Multi-centre, Double-blind, Parallel Group Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Two Anti-CD20 Monoclonal Antibodies in Combination with CHOP in Patients with CD20-Positive Diffuse Large B-cell Lymphoma
• From 2012 to till dateA Phase III Randomized, Multicenter, Two-Arm, Open-Label Trial To Evaluate The Efficacy Of T-Dm1 Compared With Treatment Of Physician’s Choice In Patients With Her2-Positive Metastatic Breast Cancer Who Have Received At Least Two Prior Regimens Of Her2-Directed Therapy
• From 2012to till dateA Randomized, Controlled, Double-Blind Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of GP2013 plus CVP vs. MabThera® plus CVP, Followed by GP2013 or MabThera® Maintenance Therapy in Patients with Previously Untreated, Advanced Stage Follicular Lymphoma
• From 2012to till datePrincipal Investigator for An Extending molecular responses with Nilotinib in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase (ENESTxtnd)
• From 2009 to till date Principal Investigator in a phase II biomarker identification trial for Erlotinib (Tarceva®) in patients with advanced pancreatic carcinoma (MARK)
• From 2009 to till date Principal Investigator for A Randomized, Double – blind, Multicenter, Phase III study of Brivanib versus Sorafenib as first – line treatment in patients with advanced Hepatocellular Carcinoma (HCC) The BRISK FL Study
• From 2007 to till date -Principal Investigator a Phase III, randomized, double blind, multicenter, placebo-controlled study of adjuvant Lapatinib in women with early Stage Erb2 over expressing breast cancer.

• Conferred “Best Doctor Award” by the ‘The Tamil Nadu Dr.MGR Medical University’ as on 1stJuly 2012
• Gold Medalist at Gujarat University, India in 1996 for DM oncology